Derek Ansel, MS, LCGC, is the Executive Director and Therapeutic Strategy Lead for Rare Disease at Worldwide Clinical Trials and a board-certified and licensed genetic counselor. He has worked in clinical research for more than ten years, focusing almost exclusively on rare and pediatric diseases, including non-malignant hematology, autoimmune diseases, metabolic disorders, movement disorders, and other genetic conditions. At Worldwide, he leads and supports corporate initiatives within rare and pediatric diseases and maintains relationships with over 45 patient-focused advocacy organizations.
Now is the time for the entire industry to understand what newborn screening and newborn sequencing programs are, how they benefit the rare disease community, and how to maximize their benefits.